DERL3 Predicts and Drives Acquired Sunitinib Resistance in Renal Cell Carcinoma by Suppressing ER Stress–ROS-Dependent Apoptosis
Zhishu Zhang, Sihan Zhang, Peihua Wang, Degang Ding, Yuanxiang Lu, Xudong Zhu · 2026
Read DERL3 Predicts and Drives Acquired Sunitinib Resistance in Renal Cell Carcinoma by Suppressing ER Stress–ROS-Dependent Apoptosis by Zhishu Zhang, Sihan Zhang, Peihua Wang, Degang Ding, Yuanxiang Lu, Xudong Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13509321.txt.
Description
Zhishu Zhang and five co-authors report a 2026 study on why kidney cancer stops responding to the drug sunitinib. The drug is a main treatment for advanced clear cell kidney cancer, but tumors often learn to resist it. The team bred resistant cancer cells in mice, then screened gene data to find what drives the change.
Six genes stayed raised in the resistant cells, and one, DERL3, stood out: silencing it brought back drug sensitivity most strongly. The gene was also high in resistant patient samples, and high levels tracked with poor response and shorter survival. Raising the gene in fresh cells made them resist the drug, in dishes and in mice. The team shows the gene shields cells by damping a stress pathway that would otherwise trigger cell death.
Catalog record
| CREATOR | Zhishu Zhang, Sihan Zhang, Peihua Wang, Degang Ding, Yuanxiang Lu, Xudong Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |